NOVEL DRUG RECONSTITUTION SYSTEMS - CURRENT MARKET LANDSCAPE

 

Over the years, novel drug reconstitution systems have been widely adopted in the healthcare sector, owing to the numerous benefits offered by these products. During our research, we identified over 55 novel drug reconstitution systems, including prefilled syringes, cartridges and infusion bags being manufactured to ease the reconstitution of drugs packaged in containers.

To order this detailed 180+ page report, please visit this - https://www.rootsanalysis.com/reports/drug-reconstitution-systems-market.html

 

 

 

Majority of the companies (32%) engaged in this domain are very large players. Examples of such companies include (in alphabetical order, established after 1900) Baxter, Fresenius Kabi, ICU Medical, Shandong Pharmaceutical Glass, Terumo, Vetter Pharma and West Pharmaceutical Services. This is followed by the share of mid-sized players (29%) in this domain. Prominent examples of mid-sized players include (in alphabetical order, established after 2000) ADIENNE, Kapsam, and Taian Youlyy Industrial. Further, majority of the companies (47%) engaged in this domain are located in Europe, particularly in Germany. This is followed by the players based in Asia-Pacific region with Japan and South Korea being the most prominent countries. Within North America, US emerged as the leading region, with the presence of seven companies.

 

As can be observed in the figure, majority of the prefilled syringes (37.5%) and infusion bags (28.6%) are dual chamber systems. On the other hand, around 18% of the infusion bags are multi chambered. Further, the cartridges are available with single and dual chambers, which make the administration of lyophilized drugs possible in an efficient and convenient manner. Further, most of the prefilled syringes have capacity of 1-2.5 mL.

 

 

As can be observed in the figure, plastic (57%) emerged as the most popular type of container fabrication material used in novel drug reconstitution systems. Ethylene vinyl acetate (EVA) emerged as the preferred plastic type used for the fabrication of majority (41%) of novel drug reconstitution system containers. EVA is a hydrophobic polymer that offers great flexibility and does not require solvents for drug delivery. Polypropylene, having demonstrated good impact strength and improved resistance to moisture, is the next popular material used in the manufacturing of novel drug reconstitution systems.

To Request for sample - https://www.rootsanalysis.com/reports/drug-reconstitution-systems-market/request-sample.html

As can be seen in the figure, Nipro and SCHOTT-KAISHA emerged as the most prominent players in this domain, developing four novel drug reconstitution systems each. It is worth mentioning that Nipro offers all the three types of novel drug reconstitution systems, namely- dual chamber prefilled syringe (2), dual chamber cartridge (1), and dual chamber infusion bag.

You may also be interested in the following titles:

1.     1DNA-Encoded Libraries: Platforms and Services Market, 2020–2030

2.     Antibody Contract Manufacturing Market, 2020 – 2030

3.     Global Autoinjectors Market, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Details

Ben Johnson

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

 

Roots Analysis

Web: https://www.rootsanalysis.com/

LinkedIn: https://in.linkedin.com/company/roots-analysis

Twitter: https://twitter.com/RootsAnalysis.com

Medium: https://medium.com/@RootsAnalysis

Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/

Quora: https://rootsanalysisinsights.quora.com/

Comments

Post a Comment

Popular posts from this blog

The microbial contract biomanufacturing market is growing at a CAGR of 8.7%, claims {Roots Analysis}

    The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment     London   Roots Analysis has announced the addition of the “ Microbial Contract Biomanufacturing Market, 2020-2030 ” report to its list of offerings.   Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various...
Read more

Manufacturing Market Continuous (Small Molecules and Biologics), 2020 – 2030 by Roots Analysis

  Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing   Roots Analysis is pleased to announce the publication of its recent study, titled, “ Manufacturing Market Continuous (Small Molecules and Biologics), 2020 – 2030 .”   The report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies with in-house expertise and contract manufacturers). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: §   A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing §   Elaborate profiles of some of the key...
Read more

A relatively larger proportion of these firms are headquartered in the US, claims Roots Analysis

  Lately, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches owing to the amplified value of smaller production facilities, which are more efficient and flexible. The increased demand for multi-product, multi-purpose, smaller batch size facilities has also prompted equipment manufacturers to revisit their product offerings.   To order this 300+ page report, which features 120+ figures and 130+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html   The USD xx billion (by 2030) financial opportunity within the modular facilities market has been analyzed across the following segments: ·        Type of Modular Construct  §   Hybrid Skid §   Plug-and-Play §   Skid-Mounted §   Truckable §   Others §   Type of Construc...
Read more